| | | | | | | | This year, the FDA will make the call on groundbreaking treatments for conditions such as Alzheimer's, NASH, and pulmonary hypertension. Here's a look at important regulatory action dates to watch. |
|
|
|
| |
| | |
|
|
| | | | | Facing exploding demand for its weight loss and diabetes drugs, Lilly grabs up a Wisconsin facility. |
|
|
| Incyte will pick up two potential first-in-class oral MRGPR antagonists in a deal worth $750 million. |
|
|
|
| |
| | |
|
|
| | | | Sponsored | | The FDA is on a mission to ensure that companies have reliable and accurate data. Data integrity (DI) continues to be a critical component in achieving GMP compliance and delivering safe and effective drugs to market, yet organizations face many challenges. Learn about the insights into the FDA's DI guidance and strategies to overcome these challenges by leveraging the cloud to achieve compliance. |
|
|
|
| |
| | |
|
|
| | | | Sponsored | | mRNA-LNP manufacturing is fraught with obstacles, resulting in higher program risk, inflated costs, and delayed market release. With the right knowledge, companies can overcome the challenges to de-risk & optimize the path to manufacturing success. |
|
|
|
| |
| | |
|
|
| | |
|
| | |
|
